牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-20 AccNo: 0001213900-19-009210 Size: 30 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-20 AccNo: 0001213900-19-009136 Size: 35 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-05-13 AccNo: 0001178913-19-001412 Size: 68 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-06 AccNo: 0001213900-19-007839 Size: 32 KB 网页链接
$灿菲特生物制药(CANF)$ F-1 - Registration statement for certain foreign private issuers Filed: 2019-05-03 AccNo: 0001213900-19-007796 Size: 768 KB 网页链接
$灿菲特生物制药(CANF)$ 美东时间 2019-05-10 拆合股: 15合1 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-01 AccNo: 0001213900-19-007572 Size: 22 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-04-15 AccNo: 0001213900-19-006324 Size: 21 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-04-12 AccNo: 0001213900-19-006211 Size: 76 KB 网页链接
$灿菲特生物制药(CANF)$ D - Notice of Exempt Offering of Securities Filed: 2019-04-11 AccNo: 0001213900-19-006184 Size: 12 KB 网页链接